Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Monica M. Bertagnolli(National Institutes of Health), Ernest T. Hawk(The University of Texas MD Anderson Cancer Center), Janet Wittes(Deloitte (United States)), G. Mabel Woloj(Pfizer (United States)), John Burn(Newcastle University), Donya Bagheri(CCS Associates (United States)), T. Raymond Foley(Lancaster General Hospital), Ann G. Zauber(Memorial Sloan Kettering Cancer Center), Scott D. Solomon(Brigham and Women's Hospital), Finlay Macrae(The Royal Melbourne Hospital), Donald K. Corle(National Cancer Institute), Rebecca B. Rosenstein(Pfizer (United States)), Jaye L. Viner(Memorial Sloan Kettering Cancer Center), Thomas Sylwestrowicz(University of Saskatchewan), Thomas Dewar(Texas Health Harris Methodist Hospital Fort Worth), John R. Saltzman(Brigham and Women's Hospital), Jie Tang(Bengbu Medical College), Daniel C. Chung(Massachusetts General Hospital), Mark Redston(Brigham and Women's Hospital), Frédéric Boisserie(Pfizer (United States)), Timothy Hess(University of Wisconsin–Madison), Craig Eagle(Pfizer (United States)), Gary Gordon, KyungMann Kim(University of Wisconsin–Madison), Ronald E. Pruitt(Nashville Medical Research Institute), Bruce Salzberg(Atlanta Gastroenterology Associates), Neville E. Hoffman(Sir Charles Gairdner Hospital), William F. Anderson(Agricultural Research Service)
New England Journal of Medicine
August 30, 2006
Cited by 1,041


Related Papers